EXTRAPULMONARY NEUROENDOCRINE CANCER

Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CANCER explained in plain language.

Never miss a new study

Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CANCER trials appear

Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug combo shows promise in Tough-to-Treat cancer trial

Disease control Not yet recruiting

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to receive either the drug combo or chemo alone. The goal is to see if…

Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CANCER

Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated May 17, 2026 17:20 UTC

EXTRAPULMONARY NEUROENDOCRINE CANCER

Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CANCER trials appear

New drug combo shows promise in Tough-to-Treat cancer trial